UNLABELLED: Nonalcoholic steatohepatitis (NASH) is characterized by hepatic lipid accumulation combined with inflammation, which can ultimately progress into cirrhosis. Recently, we demonstrated that deletion of scavenger receptors (SRs) CD36 and SR-A in hematopoietic cells reduced hepatic inflammation. In addition to uptake of modified lipoproteins, CD36 and SR-A are also involved in other functions that can activate the inflammatory response. Therefore, the actual trigger for SR activation during NASH is unclear. Here, we hypothesized that hepatic inflammation is triggered by recognition of oxidized LDL (oxLDL) by Kupffer cells (KCs). To inhibit recognition of oxLDL by KCs, low-density lipoprotein receptor (Ldlr(-/-) ) mice were immunized with heat-inactivated pneumococci, which were shown to induce the production of anti-oxLDL immunoglobulin M (IgM) antibodies, due to molecular mimicry with oxLDL. The mice received a high-fat, high-cholesterol diet during the last 3 weeks to induce NASH. Immunization with pneumococci increased anti-oxLDL IgM levels and led to a reduction in hepatic inflammation, as shown by reduced macrophage, neutrophil, and T cell infiltration, and reduced gene expression of tumor necrosis factor (Tnf), interleukin-6 (Il-6), interleukin-1β (Il-1b), monocyte chemoattractant protein 1 (Mcp1), and fibrosis-related genes. In immunized mice, KCs were smaller and showed fewer cholesterol crystals compared with nonimmunized mice. CONCLUSION: Antibodies to oxLDL play an important role in the pathogenesis of NASH. Therefore, the potential of phosphorylcholine-based vaccination strategies as a novel tool for the prevention and therapy of NASH should be tested in the future.
UNLABELLED: Nonalcoholic steatohepatitis (NASH) is characterized by hepatic lipid accumulation combined with inflammation, which can ultimately progress into cirrhosis. Recently, we demonstrated that deletion of scavenger receptors (SRs) CD36 and SR-A in hematopoietic cells reduced hepatic inflammation. In addition to uptake of modified lipoproteins, CD36 and SR-A are also involved in other functions that can activate the inflammatory response. Therefore, the actual trigger for SR activation during NASH is unclear. Here, we hypothesized that hepatic inflammation is triggered by recognition of oxidized LDL (oxLDL) by Kupffer cells (KCs). To inhibit recognition of oxLDL by KCs, low-density lipoprotein receptor (Ldlr(-/-) ) mice were immunized with heat-inactivated pneumococci, which were shown to induce the production of anti-oxLDL immunoglobulin M (IgM) antibodies, due to molecular mimicry with oxLDL. The mice received a high-fat, high-cholesterol diet during the last 3 weeks to induce NASH. Immunization with pneumococci increased anti-oxLDL IgM levels and led to a reduction in hepatic inflammation, as shown by reduced macrophage, neutrophil, and T cell infiltration, and reduced gene expression of tumor necrosis factor (Tnf), interleukin-6 (Il-6), interleukin-1β (Il-1b), monocyte chemoattractant protein 1 (Mcp1), and fibrosis-related genes. In immunized mice, KCs were smaller and showed fewer cholesterol crystals compared with nonimmunized mice. CONCLUSION: Antibodies to oxLDL play an important role in the pathogenesis of NASH. Therefore, the potential of phosphorylcholine-based vaccination strategies as a novel tool for the prevention and therapy of NASH should be tested in the future.
Authors: Christoph J Binder; Sohvi Hörkkö; Asheesh Dewan; Mi-Kyung Chang; Emily P Kieu; Carl S Goodyear; Peter X Shaw; Wulf Palinski; Joseph L Witztum; Gregg J Silverman Journal: Nat Med Date: 2003-05-12 Impact factor: 53.440
Authors: R K Tangirala; W G Jerome; N L Jones; D M Small; W J Johnson; J M Glick; F H Mahlberg; G H Rothblat Journal: J Lipid Res Date: 1994-01 Impact factor: 5.922
Authors: Janin Henkel; Charles Dominic Coleman; Anne Schraplau; Korinna Jӧhrens; Daniela Weber; José Pedro Castro; Martin Hugo; Tim Julius Schulz; Stephanie Krämer; Annette Schürmann; Gerhard Paul Püschel Journal: Mol Med Date: 2017-03-21 Impact factor: 6.354
Authors: Sofie M A Walenbergh; Tom Houben; Tim Hendrikx; Mike L J Jeurissen; Patrick J van Gorp; Anita C E Vreugdenhil; Marlou P Adriaanse; Wim A Buurman; Marten H Hofker; Antonella Mosca; Patrick J Lindsey; Anna Alisi; Daniela Liccardo; Nadia Panera; Ger H Koek; Valerio Nobili; Ronit Shiri-Sverdlov Journal: Am J Gastroenterol Date: 2015-03-03 Impact factor: 10.864
Authors: Veerle Bieghs; Sofie M A Walenbergh; Tim Hendrikx; Patrick J van Gorp; Fons Verheyen; Steven W Olde Damink; Ad A Masclee; Ger H Koek; Marten H Hofker; Christoph J Binder; Ronit Shiri-Sverdlov Journal: Liver Int Date: 2013-04-25 Impact factor: 5.828
Authors: Antoinette D Hillian; Megan R McMullen; Becky M Sebastian; Sanjoy Roychowdhury; Sanjoy Rowchowdhury; Sangeeta R Kashyap; Philip R Schauer; John P Kirwan; Ariel E Feldstein; Laura E Nagy Journal: J Biol Chem Date: 2013-06-20 Impact factor: 5.157
Authors: Clara Jana-Lui Busch; Tim Hendrikx; David Weismann; Sven Jäckel; Sofie M A Walenbergh; André F Rendeiro; Juliane Weißer; Florian Puhm; Anastasiya Hladik; Laura Göderle; Nikolina Papac-Milicevic; Gerald Haas; Vincent Millischer; Saravanan Subramaniam; Sylvia Knapp; Keiryn L Bennett; Christoph Bock; Christoph Reinhardt; Ronit Shiri-Sverdlov; Christoph J Binder Journal: Hepatology Date: 2017-02-03 Impact factor: 17.425
Authors: Detlef Schuppan; Henning Grønbæk; Konstantin Kazankov; Simon Mark Dahl Jørgensen; Karen Louise Thomsen; Holger Jon Møller; Hendrik Vilstrup; Jacob George Journal: Nat Rev Gastroenterol Hepatol Date: 2019-03 Impact factor: 46.802